Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 2/20 | 0.94 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.39 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.34 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.34 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.34 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL492194 | 1.00 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL348634 | 1.00 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL2183739 | 1.00 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL222751 | 1.00 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL222752 | 1.00 | CHRNA7 (0.94) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL3128766 | 0.97 | CHRNA7 (0.90) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| Hydrochloric Acid SCHEMBL28604839 | 0.97 | CHRNA7 (0.90) | CHRNA7CHRM2CHRM1MEN1CYP2D6 | |
| SCHEMBL9431600 | 0.97 | — | — | |
| SCHEMBL17203543 | 0.97 | — | — | |
| SCHEMBL260640 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116731008-A | Washing-free fluorescent probe for marking lung cancer target spot nicotinic acetylcholine receptor and preparation method thereof | 西北大学 | 2023-09-12 | — | — | CN | claimed |
| CN-116675688-A | Fluorescent probe for detecting nicotinic acetylcholine receptor and preparation method thereof | 西北大学 | 2023-09-01 | — | — | CN | claimed |
| US-7109377-B2 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-09-19 | — | — | US | claimed |
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | claimed |
| US-6448443-B1 | GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2002-09-10 | — | — | US | claimed |
| WO-2000006525-A9 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | HARVARD COLLEGE (US) | 2000-04-20 | — | — | WO | claimed |
| WO-2000006525-A2 | SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2000-02-10 | — | — | WO | claimed |
| WO-2026085629-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2026-04-30 | — | — | WO | disclosed |
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| CN-116731008-B | Washing-free fluorescent probe for marking lung cancer target spot nicotinic acetylcholine receptor and preparation method thereof | 西北大学 | 2025-10-24 | — | — | CN | disclosed |
| CN-120443336-A | Chiral hybridization perovskite piezoelectric crystal material and preparation method and application thereof | 晋中学院 | 2025-08-08 | — | — | CN | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-0530353-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT 3? ANTAGONISTS | G.D. SEARLE & CO. (US) | 1993-03-10 | — | — | EP | disclosed |
| EP-0504679-A1 | New imidazopyridines as serotonergic 5-HT3 antagonists | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992015593-A1 | NEW IMIDAZOPYRIDINES AS SEROTONERGIC 5-HT3 ANTAGONISTS | G.D. SEARLE & CO. (US) | 1992-09-17 | — | — | WO | disclosed |
| US-5084460-A | Psychological disorders, anxiolytic agents and cognition activators | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-01-28 | — | — | US | disclosed |
| WO-1991004253-A1 | PREPARATION OF S-(-)- AND R-(+)-N-(QUINUCLIDINYL-3)-AMIDE | CHIRON LABORATORIES A.S (NO) | 1991-04-04 | — | — | WO | disclosed |
| EP-0353371-A1 | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| US-4812442-A | TREATMENT OF HYPERTENSION, CONCESTIVE HEART FAILURE | MERCK & CO., INC. (US) | 1989-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082830-A1 | Synthesis of combinatorial libraries of compounds reminiscent of natural products | TKFC, NISCH, PTGIS | CHRNA7 2063/4885CHRM2 3093/4885CHRM1 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.